Abstract
Polyethylene glycol (PEG) is widely used to provide a stealth effect in various therapeutic applications. However, an increased occurrence of anti-PEG antibodies in patients poses a risk that can lead to anaphylactic side effects, as well as an accelerated blood clearance effect, which in turn reduces the efficacy of PEG-based delivery vectors. One of these PEG-containing vectors are lipid nanoparticles (LNPs), which effectively deliver nucleic acids. Their high potential for treating a great number of diseases in the coming future was already showcased in the mRNA vaccines developed during the Covid-19 pandemic. Thus, the aim of our study was to formulate LNP systems utilizing linear polyglycerol (lPG) as an alternative stealth polymer, to escape anti-PEG antibodies while enabling mRNA delivery. Our study showed that PG-functionalized LNPs had negligible binding to IgG anti-PEG antibodies, while successfully delivering eGFP mRNA into HepG2 cells with comparable transfection efficacy as PEGylated LNPs.
Supplementary materials
Title
Polyglycerol-based Lipids: A Next-Generation Alternative to PEG in Lipid Nanoparticles for Advanced Drug Delivery Systems (Supporting Information)
Description
Supporting Information (NMR) for "Polylgycerol-based Lipids: A Next-Generation Alternative to PEG in Lipid Nanoparticles for Advanced Drug Delivery Systems"
Actions